These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36962104)

  • 1. Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines.
    Pelzer PT; Seeley J; Sun FY; Tameris M; Tao L; Yanlin Z; Moosan H; Weerasuriya C; Asaria M; Jayawardana S; White RG; Harris RC
    PLOS Glob Public Health; 2022; 2(5):e0000076. PubMed ID: 36962104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Jul; ():. PubMed ID: 36865172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the health and economic impacts ofM72/AS01
    Sumner T; Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Bakker R; Scarponi D; Hatherill M; Menzies NA; White RG
    Vaccine; 2024 Feb; 42(6):1311-1318. PubMed ID: 38307747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.
    Clark RA; Portnoy A; Weerasuriya CK; Sumner T; Bakker R; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Sep; ():. PubMed ID: 37808744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of routine adolescent vaccination with an M72/AS01
    Harris RC; Quaife M; Weerasuriya C; Gomez GB; Sumner T; Bozzani F; White RG
    Nat Commun; 2022 Feb; 13(1):602. PubMed ID: 35105879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
    Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
    Front Immunol; 2020; 11():1806. PubMed ID: 33133057
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
    Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
    Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2b Controlled Trial of M72/AS01
    Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
    N Engl J Med; 2018 Oct; 379(17):1621-1634. PubMed ID: 30280651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
    Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
    Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Analysis of a Trial of M72/AS01
    Tait DR; Hatherill M; Van Der Meeren O; Ginsberg AM; Van Brakel E; Salaun B; Scriba TJ; Akite EJ; Ayles HM; Bollaerts A; Demoitié MA; Diacon A; Evans TG; Gillard P; Hellström E; Innes JC; Lempicki M; Malahleha M; Martinson N; Mesia Vela D; Muyoyeta M; Nduba V; Pascal TG; Tameris M; Thienemann F; Wilkinson RJ; Roman F
    N Engl J Med; 2019 Dec; 381(25):2429-2439. PubMed ID: 31661198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials.
    Wilson L; Gracie L; Kidy F; Thomas GN; Nirantharakumar K; Greenfield S; Manaseki-Holland S; Ward DJ; Gooden TE
    BMC Infect Dis; 2023 Feb; 23(1):120. PubMed ID: 36829123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis.
    Jayawardana S; Weerasuriya CK; Pelzer PT; Seeley J; Harris RC; Tameris M; Tait D; White RG; Asaria M
    NPJ Vaccines; 2022 Nov; 7(1):138. PubMed ID: 36344523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of the M72/AS01
    Ji Z; Jian M; Chen T; Luo L; Li L; Dai X; Bai R; Ding Z; Bi Y; Wen S; Zhou G; Abi ME; Liu A; Bao F
    Front Immunol; 2019; 10():2089. PubMed ID: 31552037
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing tuberculosis vaccine efficacy trials - lessons from recent studies.
    Ginsberg AM
    Expert Rev Vaccines; 2019 May; 18(5):423-432. PubMed ID: 30892969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tuberculosis vaccines: advances in clinical development and modelling.
    Weerasuriya CK; Clark RA; White RG; Harris RC
    J Intern Med; 2020 Dec; 288(6):661-681. PubMed ID: 33128834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of New TB Vaccines: Recent Advances and Next Steps.
    Hatherill M; White RG; Hawn TR
    Front Microbiol; 2019; 10():3154. PubMed ID: 32082273
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
    Gillard P; Yang PC; Danilovits M; Su WJ; Cheng SL; Pehme L; Bollaerts A; Jongert E; Moris P; Ofori-Anyinam O; Demoitié MA; Castro M
    Tuberculosis (Edinb); 2016 Sep; 100():118-127. PubMed ID: 27553419
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.